Our History
| 2006 | First identification of pluripotent NPCs |
| 2012 | Differentiated erythropoietin-producing cells from human iPS cells for the first time, and showed that its transplantation can cure anemia of renal anemia model mice |
| 2013 | Developed the method to induce differentiation of human iPS cells to renal cells and first succeeded in producing three-dimensional mini-kidney tissue |
| 2015 | Demonstrated cell therapy of NPCs prepared from human iPS cells reduced renal damage in AKI model mice (ischemia-reperfusion model) |
| 2017 | Developed a method to induce NPCs from human iPS cells with high efficiency For the first time, we succeeded in inducing highly efficient differentiation of ureteric bud, a precursor cell that derives the lower urinary tract from human iPS cells |
| 2018 | Demonstrated Reducing renal injury in acute renal injury model mice (drug-induced renal injury model) by cell therapy of human iPS cells deived-NPCs Successful expansion of human iPS cell-derived NPCs over 100 times by the expansion culture method A cell surface antigen of human iPS cell-derived NPCs was identified and an isolation method was developed Developed a cryopreservation method that maintains approximately 70% survival rate of human iPS cell-derived NPCs Started joint development of a transplantation device |
| 2019 | September 20, 2019 Established RegeNephron Co., Ltd. |
| 2020 | February 26, 2020 Changed the company name to Rege Nephro Co., Ltd. Signed a joint research agreement with Kyoto University Secured an exclusive patent license agreement from Kyoto University Successfully raised 360 million yen in our first seed round Concluded a joint research agreement with ABI Co., Ltd. Signed a joint research agreement with Nikkiso Co., Ltd. |
| 2021 | Successfully raised 100 million yen in Seed Round 2 funding Relocated our headquarters to the Med-Pharm Collaboration bldg. at Kyoto University in Ukyo-ku, Kyoto |
| 2022 | Successfully raised 1.392 billion yen in our Series A funding round Concluded a joint research agreement with AstraZeneca Signed a joint research agreement with Mitsui Chemicals, Inc. |
| 2023 | Akifumi Morinaka appointed Representative Director and Chief Executive Officer Signed a joint research agreement with Toyo Seikan Group Holdings, Ltd. and Shimadzu Corporation Joint Research Agreement Signed with Abu Dhabi Stem Cells Center Initiation of Phase 2a Clinical Trial for RN-104, an ADPKD Treatment Drug |
| 2024 | Received the Regenerative Medicine Innovation Award at the 23rd Congress of the Japanese Society for Regenerative Medicine Completed a Series B funding round, raising 2.5 billion yen Entered into a collaborative research agreement with Roche Ltd. |
| 2025 | Signed a joint research agreement with FUJIFILM Corporation Patient enrollment for the Phase 2a clinical trial of RN-104 as a treatment for ADPKD has been completed. Completed the acquisition of Tamibarotene-Related Assets from Syros Pharmaceuticals |
